Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by guildwood1on Jun 11, 2018 4:30pm

352 Views

Post# 28156437

RE:RE:RE:ATE Chart Update

I agree with Nicholas 100%. This looks like an imminent technical breakout. The news will just add rocket fuel to the fire assuming warrant converstions dont completely crush the momentum. Imo theyll be headwinds at best.

ndaloisi wrote:

TBLegend wrote: No point of even looking at charts on this man, this one is all about news / partnerships. Nothing else is going to make it rock.

TB

I have used the chart to time my entries since ATE started to move up .. first buy for me was $0.20

Price started to move up in the middle of the last trial, word must have gotten out early. Trend remains intact here and the chart once again looks good so I think ATE continues up from here regardless of when the news comes.